KTE-X19 Shows Efficacy as Treatment of MCL in the ZUMA-2 Trial
David Miklos, MD, PhD, explains the rationale behind the ZUMA-2 trial of KTE-X19 as well as the efficacy of the drug.
David Miklos, MD, PhD, clinical director of the CAR T-Cell Therapy Program and Associate Professor of Medicine at the Stanford University Medical Center, explains the rationale behind the ZUMA-2 trial of KTE-X19 as well as the efficacy of the drug.
The ZUMA-2 trial was for patients with mantle cell lymphoma (MCL) who had failed 2 prior lines of therapy and were refractory to BTK inhibitors, and Miklos says that once a patient fails the BTK inhibitor, the patients are usually not able to achieve long-term remissions.
He highlights the overall response rate and complete remission in the trial, and the durable response rate for patients who had follow-up of 2 years. MCL has an important leukemic stage in which physicians could use blood-based next-generation sequencing technologies such as the ClonoSEQ assay to detect the number of cancer cells in a patient, Miklos says, and a portion of the patients in ZUMA-2 who were tested that way showed undetectable minimal residual disease.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
